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Abstract
Development of resistance to therapy continues to be a serious clin-
ical problem in breast cancer management. Cancer stem/progenitor
cells have been shown to play roles in resistance to chemo- and
radiotherapy. Here, we examined their role in the development of
resistance to the oestrogen receptor antagonist tamoxifen. Tamoxi-
fen-resistant cells were enriched for stem/progenitors and
expressed high levels of the stem cell marker Sox2. Silencing of the
SOX2 gene reduced the size of the stem/progenitor cell population
and restored sensitivity to tamoxifen. Conversely, ectopic expres-
sion of Sox2 reduced tamoxifen sensitivity in vitro and in vivo.
Gene expression profiling revealed activation of the Wnt signalling
pathway in Sox2-expressing cells, and inhibition of Wnt signalling
sensitized resistant cells to tamoxifen. Examination of patient
tumours indicated that Sox2 levels are higher in patients after
endocrine therapy failure, and also in the primary tumours of
these patients, compared to those of responders. Together, these
results suggest that development of tamoxifen resistance is driven
by Sox2-dependent activation of Wnt signalling in cancer stem/
progenitor cells.
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Introduction
Breast cancer is the most common female cancer and approximately
70–75% of cases express oestrogen receptor alpha (ERa). Tamoxi-
fen, an oestrogen antagonist in the breast, has been the standard
endocrine therapy for women with ERa-positive breast cancer for
many years and remains so for premenopausal and a substantial
number of postmenopausal patients (Jordan & O’Malley, 2007). In
many cases, however, resistance to endocrine therapy develops,
although ERa expression is maintained in most tumours that acquire
resistance (Ali & Coombes, 2002).
The potential mechanisms underlying this resistance to endocrine
therapy involve ER-coregulatory proteins and cross-talk between the
ER pathway and other growth-factor signalling networks (Osborne
et al, 2005). A growing body of evidence is accumulating supporting
the hypothesis that cancer stem cells, or tumour-initiating cells, drive
and maintain many types of human malignancies (Diehn et al,
2009). The cancer stem cell hypothesis has shed new light on the
development of resistance to therapy, proposing that there exists a
pool of malignant cells with stem/progenitor cell properties and
increased capacity to resist common chemotherapeutic treatments,
compared to their more differentiated non-tumourigenic counter-
parts, and therefore responsible for tumour recurrence after treat-
ment (Reya et al, 2001). Breast cells with the phenotype
CD44+CD24/lowlineage isolated from metastatic pleural effusions
by fluorescence activated cell sorting (FACS) are highly enriched for
tumour-initiating cells (Al-Hajj et al, 2003). Importantly, the
CD44+CD24/low cell population increases in size after chemother-
apy and is associated with enhanced ability to form mammospheres,
suggesting that these cells are more resistant to treatment (Li et al,
2008). In addition, normal and cancer breast epithelial cells with
increased aldehyde dehydrogenase activity (ALDH) show stem/pro-
genitor cell propertiesin vitro and in vivo and are associated with
poor clinical outcome (Ginestier et al, 2007). Finally, poorly differen-
tiated breast tumours contain a higher proportion of cancer stem
cells than well-differentiated cancers (Pece et al, 2010).
Previously, we observed that oestrogen reduces the pool of
breast stem cells while tamoxifen has the opposite effect (Simoes
et al, 2011). The relevance of the increase in the proportion of can-
cer stem cells upon tamoxifen treatment is intriguing in the context
of the development of tamoxifen resistance in breast cancer
patients. Furthermore, normal and cancer stem cells share pheno-
types that may reflect the activity of common signalling pathways,
such as high expression of NANOG, OCT4 and SOX2, which is
reduced by oestrogen (Simoes et al, 2011). In breast tumours, an
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embryonic stem cell (ES)-like signature characterized by activation
of targets of Nanog, Oct4 and Sox2 is associated with high-grade ER-
negative tumours and with aggressive tumour behaviour (Ben-Po-
rath et al, 2008), supporting the possibility that ES genes contribute
to the stem cell-like phenotype found in many tumours.
Here, we present evidence that Sox2, a transcription factor that is
key in maintaining pluripotent properties of stem cells, is a crucial
player in the development of resistance to tamoxifen in ER-positive
breast cancer cells. Sox2 overexpression increases the proportion of
breast cancer stem/progenitor cells by activating the Wnt signalling
pathway, thereby rendering the cells insensitive to the growth inhib-
itory effects of tamoxifen. These findings, together with the observa-
tion that Sox2 levels are elevated in the primary tumours of patients
that do not respond to endocrine therapy, suggest that Sox2 could
represent a prognostic factor for development of resistance to
tamoxifen and that Wnt signalling may be an attractive therapeutic
target in these patients.
Results
Increased tumourigenicity during the development of tamoxifen
resistance compromises ER transcriptional activity
The development of tamoxifen resistance in breast cancer cells
was used as a model for the acquisition of resistance to oestrogen
antagonists that occurs in breast cancer patients. The oestrogen
sensitive MCF-7 breast cancer cell line was cultured in the pres-
ence of tamoxifen or, in parallel, with the carrier ethanol. Ini-
tially, cell growth rates were very much reduced in the presence
of tamoxifen, but eventually cells adapted to the new environ-
ment leading to two new sub-lines: MCF-7TamR (resistant to
tamoxifen treatment) and control MCF-7c cells. The control MCF-
7c cells are indistinguishable from the parental MCF-7 cells with
respect to their proliferation capacity in normal growth medium,
which is also similar to the MCF-7TamR cells (Fig 1A). As
expected, control cell proliferation was reduced by tamoxifen,
while MCF-7TamR cells grew at a similar rate, independently of
the presence of tamoxifen (Fig 1B). Subcutaneous transplantation
of MCF-7TamR cells to athymic mice led to larger and faster
growing tumours compared to the parental MCF-7 cells, indicating
their increased tumourigenic potential (Fig 1C). Immunoblot
analysis revealed that MCF-7TamR cells remain ERa positive (ERa
will be referred to as ER), like parental MCF-7 cells (Fig 1D).
Despite constant levels of ER expression, ER transcriptional activ-
ity was lower in MCF-7TamR cells than in control cells in the
context of a consensus oestrogen response element (Fig 1E). In
addition, expression of the progesterone receptor (PR), a well-
known ER target gene, was strongly reduced in MCF-7TamR cells
(Fig 1F). These results indicate that MCF-7TamR cells are more
tumourigenic than parental MCF-7 cells and, although they
Figure 1. Characterization of MCF-7TamR cells.
A Proliferation assay of MCF-7 (wt), MCF-7c (control) and MCF-7TamR (tamoxifen resistant) cells (n = 3).
B Proliferation assay of MCF-7c and MCF-7TamR cells treated with ethanol (OH) or 5 9 107 M tamoxifen (Tam) (n = 3).
C Tumour growth curve of MCF-7c and MCF-7TamR cells implanted s.c. in athymic mice in the presence of an exogenous slow release, oestrogen implant (n = 5 mice/
group).
D Western blot analysis of ERa expression in MCF-7c (c) and MCF-7TamR cells.
E MCF-7 (grey bars), MCF-7c (white bars) and MCF-7TamR (black bars) cells were transfected with a reporter plasmid containing three copies of a consensus ERE
driving a luciferase reporter in the presence of the carrier ethanol (OH) or 5 9 107 M tamoxifen (Tam) or 108 M oestrogen (E2). In all transfections, b-galactosidase
activity was used to control for transfection efficiency (n = 5) **p = 0.007 by t-test.
F Progesterone receptor expression in control (MCF-7c) and resistant (TamR) cells by Western blot analysis.
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express comparable levels of ER, its transcriptional activity is
reduced in MCF-7TamR cells.
Tamoxifen resistant cells express high levels of SOX2
We have recently shown that the embryonic stem cell markers NA-
NOG, OCT4 and SOX2 are expressed in normal breast stem cells
and at higher levels in breast tumour cells and that their expression
is reduced during cell differentiation (Simoes et al, 2011). Therefore,
we wished to determine whether the expression of NA-
NOG, OCT4 and SOX2 is differentially modulated during develop-
ment of tamoxifen resistance. Real-time PCR analysis showed that
the level of expression of SOX2 was 30-fold higher in MCF-7TamR
cells than in control cells. In comparison, the expression levels
of NANOG and OCT4 were not strongly affected (Fig 2A). In agree-
ment with the PCR data, the levels of Sox2 protein were also clearly
elevated in MCF-7TamR cells, although they were lower than Sox2
levels in undifferentiated human embryonal carcinoma stem cells
(NTera2/D1 cell line) (Fig 2B). Finally, immunofluorescence analy-
sis showed that Sox2 was strongly expressed in 20–30% of the
MCF-7TamR cells (Fig 2C). These results indicate that Sox2 expres-
sion levels are higher in a subpopulation of tamoxifen resistant cells
than in parental breast cancer cells.
Development of tamoxifen resistance in breast cancer cells
increases the proportion of stem/progenitor cells
To monitor whether the self-renewal capacity of the breast stem/
progenitor cell population was affected by the development of
tamoxifen resistance, the efficiency of mammosphere formation was
examined. We observed that MCF-7TamR cells formed a signifi-
cantly higher number of primary and secondary mammospheres
than the control cells, indicating increased self-renewal capacity
(Fig 3A). Quantitative PCR analysis showed that SOX2 expression is
higher in primary and secondary mammospheres than in cells
grown in adherent differentiating cultures (Fig 3B), mirroring the
numbers of spheres formed. Furthermore, MCF-7TamR cells
expressed higher levels of SOX2 than control cells, both in adherent
and suspension conditions (Fig 3B). In contrast, although the
expression of NANOG and OCT4 was higher in mammospheres
than in adherent cultures, as previously shown (Simoes et al, 2011),
there were no significant differences between their levels of expres-
sion in MCF-7TamR and control cells (supplementary Fig 1A).
These findings suggest that Sox2 is relevant to the development of
resistance to tamoxifen.
In breast carcinomas, a cell population with the phenotype
CD44+CD24/low has been shown to be enriched for tumourigenic
stem/progenitor cells (Al-Hajj et al, 2003). FACS analysis showed a
significant increase in the proportion of CD44+CD24/low cells in
secondary mammospheres when compared to cells grown in adher-
ent cultures, both in control and MCF-7TamR cells, although this
increase was significantly stronger in tamoxifen resistant cells than
in MCF-7c cells (Fig 3C and supplementary Fig 1B and D). In
addition, we determined the percentage of EMA+CALLA+ cells,
since sorting for this cell population has been shown to enrich for
normal (Clayton et al, 2004) and cancer (Simoes et al, 2011) breast
stem/progenitor cells. Indeed, the proportion of EMA+CALLA+
cells was higher in mammospheres than in adherent cultures and
Figure 2. MCF-7TamR cells express high levels of SOX2.
A Transcript levels of NANOG, OCT4 and SOX2 in adherent MCF-7c and MCF-7TamR (TamR) cells were quantified by real-time PCR and presented as fold induction
with MCF-7c value set as 1 (n = 5) *p = 0.03, #p = 0.023, **p = 0.004 by t-test.
B Immunoblots of Nanog, Oct4, Sox2 and b-tubulin (loading control) in MCF-7c and MCF-7TamR cells. NTera2/D1 (NT2) cells were used as positive control for the
expression of the stem cell markers.
C Immunofluorescence analysis of Sox2 expression in MCF7c and MCF-7TamR cells. Scale bar = 40 lm.
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was highest in MCF-7TamR cells (Fig 3D and supplementary
Fig 1C). These results suggest that MCF-7TamR cells contain a
higher percentage of stem/progenitor cells than parental breast can-
cer cells.
Previous studies have shown an association between the
CD44+CD24/low phenotype and invasion (Sheridan et al, 2006).
Consistent with this, MCF-7TamR cells exhibited an increased
invasion capacity through Matrigel, compared with control cells
(Fig 3E). Isolated stem cells with the phenotype CD44+CD24/low
displayed a significant increase in their capacity to migrate in
Transwell assays (supplementary Fig 1E), and particularly to invade
through Matrigel (Fig 3F), compared to cells of the reverse pheno-
type. Furthermore, this increase was more evident in stem cells iso-
lated from MCF-7TamR than more differentiated cells (Fig 3F).
These results show that tamoxifen resistant cells possess higher
invasion capacity than parental breast cancer cells and that this
phenotype correlates with the proportion of
CD44+CD24/low cells.
Inverse correlation of ER and Sox2 protein levels in tamoxifen
resistant breast cancer cells
Breast stem/progenitor cells lack or express low levels of ER (Clay-
ton et al, 2004; Liu et al, 2008). To examine the relationship
between ER and Sox2 expression, immunofluorescence analysis was
Figure 3. MCF-7TamR cells contain a higher proportion of stem cells than parental cells.
A Primary (I MS) and secondary (II MS) mammosphere efficiency formation from MCF-7c and MCF-7TamR cells represented as the percentage of mammospheres
formed (n = 5) **p = 0.003, ##p = 0.008 by t-test.
B SOX2 mRNA expression levels in MCF-7c and MCF-7TamR cells grown in adherent (Adh) or mammosphere (I MS and II MS) cultures were quantified by real-time
PCR (n = 3).
C, D Flow cytometry analysis of (C) CD44+/CD24/low (n = 5, *p = 0.028 **p = 0.0045 by t-test) and (D) EMA+/CALLA+ (n = 3, **p = 0.0021, ##p = 0.0028 by t-test) stem
cell populations in MCF-7c and MCF-7TamR cells cultured as adherent cells (Adh) or as secondary mammospheres (II MS), represented as the percentage of cells
with the indicated phenotype within the total population.
E Matrigel invasion assay was performed using adherent MCF-7c and MCF-7TamR cells. The photographs on the right show a representative field (n = 3) **p = 0.001
by t-test. Scale bar = 100 lm.
F Matrigel invasion assay was performed using secondary mammospheres from MCF-7c and MCF-7TamR cells FACS-sorted to isolate CD44+CD24/low (44+24) stem
cells and the remaining cell population lacking CD44+z24/low cells (Not) (n = 3) **p < 0.001 by t-test.
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performed. As shown previously, Sox2 expression was difficult to
detect in control MCF-7c cells, whereas it was expressed in around
20–30% of MCF-7TamR cells (Fig 2C and 4A). Although MCF-7 cells
express ER, they do so at quite variable levels and cells with the
highest levels of ER expression did not express Sox2, while cells
with the highest levels of Sox2 displayed the lowest levels of ER
(Fig 4A). When 300 cells from random fields from three indepen-
dent experiments were counted, approximately 30% of MCF-7TamR
cells were found to express Sox2, and of those Sox2-positive cells,
70% expressed low levels of ER and 30% expressed a high level of
ER (Fig 4B). Representative plots obtained using ImageJ 3D colour
inspector analysis further demonstrate the segregation between ER
and Sox2 expressing cells (Fig 4B). Similar results were obtained
using the ER-positive breast cancer cell lines T-47D and ZR-75-1
(supplementary Fig 2A and B).
To enrich for stem/progenitor cells, we cultured MCF-7TamR
cells as mammospheres. Western blot analysis showed that ER
expression was reduced in mammosphere cultures (Fig 4C). More-
over, Sox2-positive cells generally did not express ER in mammo-
spheres, as shown by immunofluorescence (Fig 4D and
supplementary Fig 2C). Furthermore, FACS sorted CD44+CD24/
low cells expressed barely detectable levels of ER, both when iso-
lated from control and MCF-7TamR cultures (Fig 4E). As expected,
Sox2 was detected at the highest levels in the CD44+CD24/low cells
isolated from MCF-7TamR mammospheres and was consistently
absent from the population lacking this phenotype (Fig 4E). These
results indicate that the most undifferentiated stem cell-like Sox2-
positive cells do not express ER. These findings support the associa-
tion between the CD44+CD24/low phenotype of breast cancer
tamoxifen-resistant cells and Sox2 expression and suggest that cells
expressing high levels of Sox2 will be more resistant to tamoxifen.
Alteration of SOX2 expression levels affects stem cell content
and tamoxifen sensitivity
To determine the relevance of Sox2 expression to the stem cell phe-
notype, we reduced endogenous SOX2 levels in MCF-7TamR cells
using siRNA. Transfection of two different siRNA sequences directed
against Sox2 resulted in a strong reduction of Sox2 expression, as
detected by immunofluorescence, while a control sequence did not
have any effect (supplementary Fig 3A). Downregulation of Sox2
expression led to a significant inhibition of mammosphere formation
by MCF-7TamR cells (Fig 5A), and a significant reduction in the per-
centage of cells with the phenotype CD44+CD24/low (Fig 5B and
supplementary Fig 3C). Furthermore, MCF-7TamR cells contained a
significantly higher population of ALDEFLUOR-positive cells, this is
with high ALDH activity (Ginestier et al, 2007), than control cells
(supplementary Fig 3B) and these cells expressed higher ALDH1A3
and Sox2 levels than the ALDEFLUOR-negative subpopulation (sup-
plementary Fig 3E). Therefore, the ALDEFLUOR-positive subpopula-
tion was also specifically reduced by Sox2 siRNA, while it was not
affected by a control siRNA (Fig 5C and supplementary Fig 3D).
We have previously shown that stable overexpression of Sox2 in
MCF-7 cells increases the frequency of stem cells and their capacity
for invasion, properties associated with tumourigenesis and poor
prognosis (Simoes et al, 2011). Importantly, breast cancer cells over-
expressing Sox2 showed an enhanced resistance to the antiprolifera-
tive effects of tamoxifen treatment in vitro (Fig 5D) and in
vivo (Fig 5E). In contrast, overexpression of Nanog or Oct4 did not
affect sensitivity to tamoxifen (supplementary Fig 3F). On the other
hand, stable downregulation of Sox2 expression (supplementary
Fig 3G) in MCF-7TamR cells rendered them more sensitive to tamox-
ifen (Fig 5F). This reduction in cell viability under tamoxifen treat-
ment was due to increased apoptosis rather than cell cycle arrest
(supplementary Fig 4A and B, respectively). Finally, we wished to
evaluate whether Sox2 levels are relevant to tamoxifen sensitivity in
other tamoxifen resistance models. Reduction of endogenous Sox2
expression levels in tamoxifen resistant BT-474 cells (supplementary
Fig 3H) was sufficient to increase their sensitivity to tamoxifen
(Fig 5G). In addition, we developed breast cancer T47D cells resis-
tant to tamoxifen (T47DTamR) by exposing them to tamoxifen for a
period of over 8 months. Development of resistance to tamoxifen led
to elevated endogenous Sox2 levels and decreased PR expression
(supplementary Fig 4C), as observed in MCF-7TamR cells. Further-
more, Sox2 downregulation by specific siSox2 sequence in
T47DTamR cells significantly reduced their resistance to tamoxifen
(supplementary Fig 4D). Collectively, these results demonstrate that
Sox2 plays a key role in the maintenance of the increased stem cell
population associated with the development of tamoxifen resistance.
Elevated SOX2 expression levels correlate with poor prognosis
and development of recurrence in breast cancer patients
The above findings raised the possibility that Sox2 expression may
be altered during development of tamoxifen resistance in patients.
To test this hypothesis, we examined a series of ER-positive breast
tumour samples from 55 patients that had received tamoxifen ther-
apy and a minimum of 6-year follow-up was available (supplemen-
tary Table S1). The cohort included patients for whom the
endocrine therapy was successful (responders) and the tumour had
not returned over a period of 8 years (n = 33 patients) and in which
Sox2 was weakly expressed in a low percentage of cells (Allred
score ≤2) (Fig 6A). In contrast, in non-responder patients all pri-
mary tumours stained positive for Sox2 (22 patients); furthermore,
there was a significant increase in Sox2 expression in the recurrent
lesions (26 samples, since four of them recurred twice), compared
with the matched primary tumours. Representative photographs of
tumour samples with negative (Fig 6C), moderate (Fig 6D) and
strong (Fig 6E) Sox2 staining are shown. Interestingly, elevated
Sox2 levels significantly correlated with decreased PR expression
and increased histological grade during development of tamoxifen
resistance (Fig 6B and supplementary Table S1).
In addition, in order to determine whether the expression of
Sox2 has prognostic potential in breast cancer patients treated with
tamoxifen, we analysed publicly available patient data sets
(GSE9893, GSE12093 and GSE1379) where ER-positive patients
(n = 154, 132 and 54, respectively) had been treated with tamoxifen
therapy and a minimum of 5-year follow-up data are available. High
Sox2 levels significantly correlated with poor overall survival and
disease free survival (Fig 6F and G, and supplementary Fig 5).
Taken together, these findings suggest that Sox2 expression in pri-
mary ER-positive tumours may be a clinical prognostic biomarker
for tamoxifen resistance.
Increased expression of Sox2 leads to activation of Wnt
signalling
To unravel the mechanism of action of Sox2 in adherent and mam-
mosphere cultures of breast cancer cells, we performed global gene
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expression analysis. Comparison of the expression profiles of
Sox2-overexpressing cells with parental MCF-7 cells in adherent and
suspension culture conditions highlighted the relevance of the Wnt
signalling pathway in Sox2-overexpressing cells (supplementary
Fig 6A and B). DKK1 and AXIN2, two known Wnt target genes,
were among the most significant differentially expressed genes in
Sox2-overexpressing cells. Their increased levels of expression due
to Sox2 overexpression were confirmed by qPCR (Fig 7A). Inhibi-
tion of Sox2 expression in tamoxifen resistant cells using two differ-
ent Sox2 shRNAs was sufficient to reduce DKK1 and AXIN2
Figure 4. Inverse association between ER and Sox2 expression in MCF-7TamR cells.
A Coexpression of SOX2 and ER was visualized by immunofluorescence in MCF-7c and MCF-7TamR cells grown as adherent cells (scale bar = 40 lm) and,
B as secondary mammospheres at day 4 (Scale bar = 20 lm).
C Left, percentage of adherent MCF-7TamR cells that were Sox2-positive and that expressed low (lo) or high (hi) ER levels (n = 3) **p = 0.0011 by t-test. Right, 2
representative plots obtained with ImageJ 3d colour inspector analysis, in green and in red, ER and Sox2 positivity, respectively.
D Western blot analysis of ER expression levels in MCF-7c and MCF-7TamR cells grown as adherent cells (Adh) or as secondary mammospheres (II MS). GAPDH was
used as a loading control.
E Immunofluorescence analysis of Sox2 and ER expression in FACS-sorted CD44+CD24/low (44+24) stem cells and the rest of the cell population lacking
CD44+CD24/low cells (Not). Scale bar = 30 lm.
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expression (Fig 7B). Furthermore, Wnt-3a and its receptor FZD4,
also identified by microarray analysis, were induced both in tamoxi-
fen resistant cells and in Sox2-overexpressing cells, while expression
of WNT4, which inhibits Wnt/b-catenin signalling (Elizalde et al,
2011), was reduced (Fig 7C). To determine if activation of the Wnt
signalling pathway in these cells was mediated by an autocrine
pathway, we used the small-molecule porcupine inhibitor IWP-2,
which blocks Wnt secretion (Chen et al, 2009). Addition of IWP-2
Figure 5. Alteration of Sox2 expression levels affects stem cell properties.
A Mammosphere formation assay of MCF-7TamR cells transfected with siRNA. Values obtained with scramble siRNA are set as 100% (n = 3) **p = 0.01, ##p = 0.009
by t-test.
B CD44+CD24/low stem cell population analysis of primary mammospheres (n = 3) **p = 0.011, ##p = 0.01 by t-test and
C ALDEFLUOR assays in adherent cells, were all performed using MCF-7TamR cells transfected with 2 different Sox2 siRNA sequences (siSox2 1 and 2) as well as a
control siRNA sequence (siCtrl) (n = 3) **p = 0.002, ##p = 0.009 by t-test.
D Viability analysis by crystal violet (left) of MCF-7c (c), MCF-7TamR (TamR) cells and MCF-7 cells stably overexpressing Sox2 (Sox2) and control MCF-7v (v) cells (n = 5)
**p = 0.008, *p = 0.02 by t-test and (right) MTT assays of MCF-7SOX2 (SOX2) and control MCF-7v (v) cells growing in presence of increasing concentrations of
tamoxifen (from 1010 M to 106 M) (n = 5) ***p = 0.008, ##p = 0.007 by t-test.
E Tumour size 3 weeks after s.c. implantation of MCF-7c, MCF-7TamR and MCF-7SOX2 cells in athymic female mice in the presence of an exogenous slow oestrogen
supplement and with or without a tamoxifen pellet (n = 5 mice/group).
F Viability analysis by (left) crystal violet (n = 5, **p = 0.003, ##p = 0.02 by t-test) and (right) MTT assays (n = 5, *p = 0.004, ***p = 0.0008 by t-test) of MCF-7c (c),
MCF-7TamR (TamR) and MCF-7TamR cells stably transfected with shRNA against Sox2 (sh1 and sh2) and control (shC), growing in the presence of vehicle (ethanol,
OH) or tamoxifen.
G Viability analysis by crystal violet and of BT474 cells transfected with a control siRNA sequence (siCtrl) and two different Sox2 siRNA sequences (siSox2 1 and 2)
growing in the presence of vehicle (ethanol, OH) or tamoxifen at different concentrations (108 M, ##p = 0.009, #p = 0.017, 107 M, *p = 0.044, **p = 0.002 by t-
test, as indicated, n = 3).
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reduced DKK1 and AXIN2 expression in tamoxifen resistant breast
cancer cells (Fig 7D). Furthermore, IWP-2 significantly reduced the
cancer stem cell population in tamoxifen resistant cells, as con-
firmed by reduced capacity for mammosphere formation (Fig 7E)
and a reduction in the percentage of CD44+CD24/low cells
(Fig 7F). Crucially, IWP-2 restored tamoxifen sensitivity to MCF-
7TamR cells (Fig 7G) and this effect of IWP-2 was prevented upon
addition of exogenous purified Wnt-3a protein (Fig 7H). These find-
Figure 6. Sox2 expression increases during the development of tamoxifen resistance in breast cancer patients.
A Allred score for Sox2 (A) and PR staining (B). Patients with responder primary tumours (n = 33), namely those that responded to tamoxifen treatment (Resp.);
patients with non-responder primary tumours (n = 22) (Non-Resp.) and their recurrent tumours after therapy failure (Recur.). p-values were calculated by
Bonferroni multiple comparable test.
C–E Examples of Sox2 staining in (C) a tumour responsive to treatment, (D) a primary tumour not responsive to therapy and (E) a recurrent lesion from the matched
primary tumour in (D).
F Correlation between Sox2 expression and recurrence in ER-positive tamoxifen treated breast cancer patients. Box plot from the study indicated (Chanrion et al,
2008) is shown. The y-axis shows normalized expression units. Data are median centered and the 25th–75th percentiles are indicated by the closed box. The
numbers of breast carcinoma samples present are shown in parentheses and GEO accession numbers are indicated. Resp and Non Resp. tumours as above.
G The association between Sox2 expression levels and disease free survival (top) and overall survival (bottom) was evaluated by Kaplan–Meier analysis. p-values were
calculated by Cox proportional hazards regression analyses. The Sox2 low group was defined by expressing lower Sox2 levels than the median of all patients in the
study, and the rest of the patients belonged to the Sox2 high group.
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Figure 7. Sox2 overexpression leads to the activation of Wnt signalling.
A DKK1 and AXIN2 mRNA expression levels in MCF-7v (v) and MCF-7SOX2 cells grown in adherent conditions (n = 5) **p = 0.002, ##p = 0.002 by t-test.
B DKK1 (***p = 0.0001, **p = 0.009, *p = 0.042 by t-test) and AXIN2 (###p = 0.009,##p = 0.043, #p = 0.029 by t-test) mRNA expression levels in MCF-7c (c) and
MCF7TamR (TR) cells and MCF-7TamR cells stably transfected with 2 different Sox2 shRNA sequences (sh1 and sh2) as well as a control shRNA sequence (shC) grown
in adherent conditions (n = 5).
C Wnt-3a (**p = 0.008, ##p = 0.0056 by t-test), FZD4 (*p = 0.021, #p = 0.016 by t-test) and WNT4 (***p = 0.0001, ###p = 0.0015 by t-test) mRNA expression levels
in MCF-7c (c), MCF7TamR (TR), MCF-7v (v) and MCF-7SOX2 cells grown in adherent conditions (n = 5).
D DKK1 and AXIN2 mRNA expression levels in MCF-7c (c) and MCF7TamR (TR) cells treated for 48 h with 1 lM of IWP-2 or the vehicle (DMSO) (n = 3) *p = 0.012,
**p = 0.017 by t-test.
E Mammosphere formation assay from MCF-7c and MCF-7TamR (TamR) cells growing in presence of 1 lM of IWP-2 or the vehicle (DMSO) (n = 3) *p = 0.036,
**p = 0.002 by t-test.
F Flow cytometry analysis of the CD44+/CD24/low stem cell population in MCF-7TamR cells grown as mammospheres in presence of 1 lM of IWP-2 or the vehicle (D)
(n = 3) *p = 0.045 by t-test.
G Cell viability analysis by MTT assay of MCF-7c (left) and MCF-7TamR (right) cells growing in the presence of increasing concentrations of IWP-2 (from 0.5 lM to
2 lM) and in presence or absence of 107 M tamoxifen (n = 5) **p = 0.002, ##p = 0.0011 by t-test.
H Cell viability analysis by MTT assay of MCF-7c and MCF-7TamR cells growing in the presence or absence of 107 M tamoxifen, 1 lM IWP-2 and 100 ng/ml
recombinant Wnt-3a as indicated (n = 3) **p = 0.001.
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ings indicate that autocrine Wnt signalling protects breast cancer
cells from the anti-proliferative effects of tamoxifen.
Discussion
Development of resistance to tamoxifen remains an important clini-
cal problem. Here we demonstrate that tamoxifen resistant MCF-7
cells express higher levels of Sox2 than parental breast cancer cells.
In addition, tamoxifen resistant cells contain a higher proportion of
cancer stem/progenitor cells and are more invasive than parental
cells. There is an inverse correlation between ER and Sox2 expres-
sion in breast cancer cells and an association between the
CD44+CD24/low phenotype of tamoxifen-resistant breast cancer
cells and Sox2 expression. Reduction of endogenous Sox2 levels
decreases the proportion of the subpopulation of stem/progenitor
cells and enhanced Sox2 expression confers tamoxifen resistance to
MCF-7 cells in vitro and in vivo. In addition, Sox2 silencing signifi-
cantly reversed tamoxifen resistance in both the native (BT474) and
another anti-oestrogen resistance model (T47D). Importantly, evi-
dence of the potential clinical relevance was observed in a cohort of
ER-positive breast cancer patients who received tamoxifen therapy,
where high levels of Sox2 correlated with endocrine treatment fail-
ure and poor relapse-free survival. Finally, Sox2 expression leads to
Wnt signalling activation and resistance to tamoxifen. Taken
together, these findings suggest that Sox2 plays a key role in the
development of tamoxifen resistance by maintaining the cells in a
more stem cell-like state through increased autocrine Wnt signal-
ling.
Following current anti-cancer treatments a subset of cells, the
tumour-initiating cells or cancer stem cells, may reinitiate tumour
growth after therapy in many patients. Indeed, radiation-induced
enrichment of cancer stem/progenitor cells occurs in MCF-7 breast
cancer cells, suggesting that stem/progenitor cells have increased
survival mechanisms (Phillips et al, 2006; Woodward et al, 2007).
Further evidence supporting the intrinsic resistance of cancer stem
cells to treatment was provided by a study comparing breast cancer
core biopsies before and after treatment, which showed that chemo-
therapy leads to an increase in the proportion of cancer stem cells
with the phenotype CD44+CD24/low and to enhanced mammo-
sphere forming efficiency (Li et al, 2008). In addition, high ALDH
activity identifies cancer stem cells and is associated with poor prog-
nosis (Ginestier et al, 2007). Furthermore, ALDH-positive cells are
more invasive than the ALDH-negative cell population and have
increased metastatic potential (Charafe-Jauffret et al, 2009), in
agreement with our findings that MCF-7TamR cells are more inva-
sive and show a higher content of ALDH-positive cells.
Breast stem cells have been reported to lack ER or express it at
very low levels (Clayton et al, 2004), which may facilitate the resis-
tance of cancer stem cells to the antiproliferative effects of tamoxi-
fen. Consistent with this, we show that the cancer stem cells, which
express high levels of Sox2, lack or express very low levels of ER
and, therefore, they will be more resistant to tamoxifen. In fact, the
impact of reducing Sox2 expression on the proportion of stem cells
in MCF-7TamR cells suggests that Sox2 plays a relevant role in con-
ferring a less differentiated phenotype. This observation was corrob-
orated in the clinical samples where increased histological grade
significantly correlated with Sox2 expression. Accordingly, it was
shown that histologically poorly differentiated breast tumours dis-
play preferential overexpression of genes normally enriched in ES
cells (Ben-Porath et al, 2008) and that they contain a higher propor-
tion of cancer stem cells than well-differentiated cancers (Pece et al,
2010), supporting the notion that the cancer stem cell content
reflects the malignancy of the tumour (Vivanco, 2010).
The mechanisms that contribute to elevated Sox2 levels in
resistant cancers are not fully understood. The previously reported
differentiating effect of oestrogen on stem cells (Simoes et al,
2011) may be partly due to its capacity to repress Sox2, although
this effect is similar in parental MCF-7c and MCF-7TamR cells
(supplementary Fig 6C), suggesting that high expression of Sox2 in
tamoxifen resistant cells cannot simply be explained by lack of ER
activity. We observed that oestrogen reduces Sox2 mRNA expres-
sion levels already after 4 h, independently of the presence of acti-
nomycin D (supplementary Fig 6D). ER phosphorylation at Serine
118 was found to be increased in MCF-7TamR cells, consistent
with previous studies in other resistance models (Chen et al, 2013;
Sarwar et al, 2006). However, changes in Sox2 expression did not
affect Serine 118 phosphorylation (supplementary Fig 6E), indicat-
ing that the effects of Sox2 do not involve phosphorylation at this
site. Interestingly, Sox2 has been proposed to be a possible driver
of the basal-like phenotype in sporadic breast cancer because it is
expressed frequently in basal-like breast carcinomas (Rodriguez-Pi-
nilla et al, 2007). In addition, the level of Sox2 expression is
strongly correlated with tumour grade in breast cancer (Chen et al,
2008), and high expression of Sox2 has been proposed to increase
metastatic potential (Lengerke et al, 2011). Furthermore, a 3q copy
number gain (that includes the SOX2 locus) is a stronger predictor
of recurrence than grade and other features in invasive breast car-
cinoma (Janssen et al, 2003). Our results indicate that Sox2 is not
just implicated in tumourigenesis but is also involved in the devel-
opment of resistance to therapy. Ectopic expression of Sox2 in
MCF-7 cells is sufficient to render them more resistant to tamoxi-
fen treatment in vitro and in vivo, in association with increases in
the frequency of stem cells and capacity for invasion, suggesting a
potential mechanism for the development of resistance to endo-
crine therapy. In addition, our gene expression analysis highlights
the differential expression of several genes involved in the
response to drugs (supplementary Fig 6B). Consistent with these
findings, Sox2 is also implicated in the cancer stem cell phenotype
and development of chemoresistance in glioblastoma (Jeon et al,
2011) and prostate cancer (Jia et al, 2011). Most importantly, our
experimental findings were recapitulated in samples derived from
breast cancer patients that had received tamoxifen treatment.
Intriguingly, increased Sox2 levels also significantly correlated with
lower PR expression than in primary tumours, as observed in the
resistance models examined, suggesting that the ER signalling
pathway is compromised during development of tamoxifen resis-
tance. The use of a larger cohort of patients is now warranted to
explore the predictive power of Sox2 for resistance to endocrine
therapy.
Wnt signalling has recently been shown to be implicated in the
normal physiology of the mammary gland stem cells (Zeng & Nus-
se, 2010). Furthermore, altered Wnt/b-catenin pathway has been
proposed to be implicated in breast tumour initiating cells (Roarty
& Rosen, 2010), and a small molecule inhibitor of Wnt secretion
was recently reported to halt tumour growth in vivo (Proffitt et al,
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2013). Gene expression profiling of Sox2 overexpressing cells
revealed increased expression of the Wnt target genes DKK1 and
Axin2. DKK1 has been found preferentially expressed in hormone
resistant breast tumours and tumours with poor prognosis (Forget
et al, 2007). Axin2 can regulate epithelial-mesenchymal transition
by controlling Snail1 activity in breast cancer cells (Yook et al,
2006) and its expression has been shown to be upregulated in
breast tumours (Ayyanan et al, 2006). Furthermore, increased
Wnt/b-catenin signalling has been shown to be an early event in a
model of breast neoplasia (Khalil et al, 2012) and to enhance self-
renewal and mediate radiation resistance in mammary gland pro-
genitor cells (Chen et al, 2007). Our results suggest that Wnt sig-
nalling is activated in tamoxifen resistant cells through an
autocrine mechanism, since it is blocked by IWP-2, which inhibits
Wnt secretion. Moreover, the block can be rescued by exogenous
Wnt-3a, which restored hormone resistance to IWP-2-treated
tamoxifen resistant cells. Finally, there is reciprocal regulation of
Sox2 and Wnt signalling, since not only does Sox2 regulate Wnt
activity, but Wnt signals regulate Sox2, as recently reported by
Wang and colleagues, who showed that the Lgr4/Wnt/b-catenin/
Lef1 pathway controls Sox2 expression (Wang et al, 2013). Consis-
tent with these results and with a positive feedback mechanism,
we observed that treatment of MCF-7TamR cells with the Wnt
inhibitor IWP-2 reduces Sox2 expression (supplementary Fig 6F).
Together these observations highlight the relevance of the Wnt/b-
catenin signalling pathway in breast cancer and in resistance to
tamoxifen.
In normal breast, the expression levels of stem cell markers are
downregulated during the differentiation process to epithelial cells,
while their expression appears to be “reawakened” in tumour cells
(Simoes et al, 2011). Significantly, development of tamoxifen resis-
tance implies loss of ER transcriptional activity and elevated Sox2
expression, leading to Wnt signalling activation and enrichment of
the cancer stem cell population (supplementary Fig 7). Targeting
the Wnt signalling pathway may favour stem cell differentiation and
render tumour cells more sensitive to tamoxifen. The implication of
these findings is that a combination of tamoxifen and small mole-
cule inhibitors of Wnt signalling could be developed as a new treat-
ment to prevent recurrence in defined groups of breast cancer
patients.
Materials and Methods
Cell culture and establishment of TamR cells
All cells were obtained from American Type Culture Collection
(ATTC). MCF-7 cells were cultured in DMEM:F12 medium with
GlutaMAX (Gibco) supplemented with 8% foetal bovine serum,
FBS, (Sigma) and 1% penicillin/streptomycin (Sigma) at 37°C in
5% CO2. Cells were grown in the presence of ethanol, as vehicle,
and 5 9 107 M 4-OH-tamoxifen (Sigma), respectively, in DMEM:
F12 with 8% FBS for 6 months. During this time, the medium was
replaced every 3 days and the cell cultures were passaged by tryps-
inization after 70–80% confluency was reached. During the first
few weeks cell growth rates were strongly reduced by tamoxifen
treatment (no effect was ever detected by the very small dose
(<0.01% v/v) of ethanol provided to the MCF-7 control cells. Even-
tually, cell growth gradually increased, leading to the development
of the tamoxifen resistant cell line MCF-7TamR. These cells were
maintained in culture with 4-OH-tamoxifen for a further 4 months
before characterization. MCF-7c (parental control) and MCF-7TamR
have been routinely maintained in the presence of ethanol, as vehi-
cle, and 5 9 107 M of 4-OH-tamoxifen, respectively. Their cell
growth properties have remained stable since then. BT474 cells
were cultured in DMEM:F12 medium with GlutaMAX (Gibco) sup-
plemented with 8% foetal bovine serum, FBS, 5 lg/ml insulin
(Sigma) and 1% penicillin/streptomycin (Sigma) at 37°C in 5%
CO2. MCF-7GFP (MCF-7v) and MCF-7SOX2 overexpressing cells
(Simoes et al, 2011) were generated by infection with lentivirus
encoding GFP (pSin-EF2-EGFP-Pur vector) and Sox2 (pSin-EF2-
Sox2-Pur vector), respectively. Mammosphere cultures were main-
tained as in (Dontu et al, 2003). More detailed information can be
found in supplementary.
Proliferation assay
MCF-7, MCF-7c and MCF-7TamR cells were seeded at 105 cells/well
in six-well plates in normal medium. Cell numbers were determined
by counting with a haemocytometer. The medium was changed after
3 days. MCF-7c and MCF-7TamR cells were seeded in six-well plate
at 5 9 104 cells/well in six-well plates and hormone starved in
DMEM:F12 containing 8% charcoal-treated FBS for 48 h. Cells were
then washed and grown in DMEM:F12 containing 8% charcoal-trea-
ted FBS in the presence of 5 9 107 M tamoxifen or ethanol.
Mammosphere formation assay
MCF-7c and MCF-7TamR cells were plated in poly-HEMA six-well
coated plates at 5000 cells/ml. At day 7, 1 lM of calcein AM
(Sigma) was added to each well and incubated for 1 h. After solidifi-
cation in 0.3% agarose mammospheres bigger than 35 lm diameter
were counted using a Metaxpress microscope (Molecular Devices).
The mammosphere formation efficiency (shown as percentage) was
calculated by dividing the number of mammospheres formed by the
original number of single cells seeded.
Invasion assay
In vitro invasion and migration assays were performed as in (Ha-
yashida et al, 2010). More detailed information can be found in sup-
plementary.
Transient transfection and luciferase assay
MCF-7, MCF-7c and MCF-7TamR cells were seeded in six-well plate
at 2.5 9 105 cells/well and grown in charcoal-treated conditions for
48 h. The cells were transfected with the ERE-TK-luciferase reporter
(kindly provided by Prof. M Parker, London) using Lipofectamine
2000 (Invitrogen) following the manufacturer’s instructions. Each
well also received pRL b-galactosidase to normalize for transfection
efficiency (Vivanco et al,1995). After transfection, the cells were
maintained in phenol red free DMEM:F12 containing 8% charcoal
stripped FBS, treated with 108 M oestrogen or 5 9 107 M 4-OH-
tamoxifen or ethanol (vehicle) for 48 h. The cell lysates were
assayed for luciferase and b-galactosidase activities with the Lucifer-
ase Assay Kit (Promega) and the Tropix Galacto-light-plus assay
(Applied Biosystems), respectively, using a luminometer (Turner
Biosystem). The luciferase results are shown as relative light units
of luciferase activity normalized with respect to b-galactosidase
activity.
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Real-Time Polymerase Chain Reaction (PCR)
RNA was isolated using the TRIzol method (Invitrogen). Real-time
PCR was performed on a 7300 Real-Time PCR System (Applied Bio-
systems). More detailed information can be found in supplemen-
tary.
Western blot
Cell lysates were prepared directly with Laemmli sample buffer
(Sigma). Primary antibodies included; mouse anti-ERa (6F11, Novo-
castra), rabbit anti-phospho ER (S118) (2515, Cell Signaling), mouse
anti-PR (Novocastra), goat anti-SOX2 (Y17, Santa Cruz), mouse
anti-OCT3/4 (H-134, Santa Cruz), goat anti-NANOG (R&D System),
mouse anti-GAPDH (Sigma), anti-b-actin and mouse anti-b-tubulin
(Sigma). For detection an enhanced chemiluminescence detection
kit (Amersham) was used.
Immunofluorescence
Cells were cultured on cover slips, fixed with paraformaldehyde
(4% for 10 min at 4°C) and permeabilized for 20 min with PBS sup-
plemented with 0.5% of Triton X-100, followed by blocking for
20 min with TBS supplemented with 0.1% of Triton X-100 (Sigma)
and 3% of BSA and incubated for 1 h at room temperature with pri-
mary antibody: goat anti-SOX2 and mouse anti-ERa, and with sec-
ondary antibodies, anti-mouse Alexa 647 (Molecular Probes), anti-
mouse Alexa 488 (Molecular Probes), anti-goat Alexa 568 (Molecu-
lar Probes) and phalloidin-FITC (Sigma). Slides were mounted in
Vectashield with DAPI (Vector). Immunofluorescence of sorted cells
was performed on cytospin preparations (800 g for 5 min) as
described above. Mammospheres were collected by centrifugation,
fixed in paraformaldehyde 4% overnight at 4°C, permeabilized in
PBS supplemented with 1% of Triton X-100 for 1 h at room temper-
ature, blocked and incubated overnight at 4°C with primary anti-
body (anti-SOX2 and anti-ERa) followed by secondary antibodies
(anti-mouse Alexa 647, anti-goat Alexa 568) and phalloidin-FITC.
Antibody binding was visualized using a Leica confocal microscope.
Digital images were processed using Adobe Photoshop CS2 and
analysed with ImageJ image-analysis software (W. Rasband, NIH).
Fluorescence activated cell sorting (FACS)
Human epithelial membrane antigen (EMA) and common acute lym-
phoblastic leukaemia antigen (CALLA) labelling was performed as
previously described (Clayton et al, 2004). The mouse PE anti-CD24
antibody (BD, clone ML5) and mouse allophycocyanin (APC) anti-
CD44 antibody (BD, clone G44-26) were used to label CD24 and CD44.
More detailed information can be found in supplementary.
ALDEFLUOR assay
The ALDEFLUOR assay was carried out according to manufacturer’s
(Stemcell Technologies) guidelines. More details provided in supple-
mentary.
Small interfering and short hairpin RNA transfection
Small interfering RNA oligonucleotides were transfected using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s proto-
col. siRNA oligos (50 nM) were incubated with the cells for 48 h
before analysis. To transfect siRNA in suspension culture, 48 h after
the first transfection, cells were transfected again with 50 nM of siR-
NA and allowed to grow in suspension culture for 96 h. The
sequences of each Stealth™ RNAi (Invitrogen) oligonucleotide are as
follows:
siSOX2 1, HSS186041 5′ CCUGUGGUUACCUCUUCCUCCCACU 3′
siSOX2 2, HSS186045 5′ GCGUGAACCAGCGCAUGGACAGUUA 3′.
Two pLKO.1 lentivirus shRNAs vector targeted against SOX2
were purchased from Open Biosystem (sh1: TRCN0000085748; sh2:
TRCN0000085750). An empty shRNA vector was used as negative
control (shC). Lentiviruses were produced as previously described
(Simoes et al, 2011).
Xenograft analysis
All animal procedures were carried out at the SPF animal facility of
CIC bioGUNE (AAALAC-accredited) and conducted in accordance
with theGuide for the Care and Use of Laboratory Animals (Institute
of Laboratory Animal Resources NRC, 1996) and with European pol-
icies (European Commission, 1986). Protocols were approved by the
CIC bioGUNE Bioethical and Animal Welfare Committee. A total of
1 9 106 cells of MCF7c, MCF7TamR or MCF7SOX2 cells were sus-
pended in 100 ll of PBS/Matrigel (1:1) and injected s.c. into female
3- to 4-week-old BALC/c nu/nu athymic mice (Harlan), which
simultaneously received a 60-day slow release pellet containing
0.72 mg of 17b-estradiol with or without 5 mg tamoxifen (Innova-
tive Research of America). Animals were observed once a week.
Cell growth analysis
MTT assays were performed following the manufacturer’s instruc-
tions. Detailed information for this assay and crystal violet staining
can be found in supplementary.
Immunohistochemistry
Immunohistochemical staining on formalin-fixed, paraffin-embed-
ded carcinomas and non-neoplastic breast tissue was performed
using the Leica Bond-III stainer. Sox2 staining was scored on the
basis of both the percentage of positive cells and the intensity of the
staining according to the Allred score (Harvey et al, 1999). Detailed
information can be found in supplementary.
Gene expression microarray analysis
Gene expression profiles were compared between MCF-7v and MCF-
7SOX2 cells cultured in adherent or suspension conditions using the
Human HT-12 v1 BeadChips (Affymetrix, Santa Clara, CA). Detailed
information can be found in supplementary. Microarray data are
available in the ArrayExpress database (www.ebi.ac.uk/arrayex-
press) under accession number E-MEXP-3984.
Statistical analysis
Data from at least three independent experiments are expressed as
means  SD. Clinical data were analysed as indicated in the figure
legends. Each data point of real-time PCR, MTT, mammosphere for-
mation, luciferase activity assays and proliferation was run at least
in triplicates and independent experiments were performed at least
three times. Student’s t-test was used to determine statistically sig-
nificant differences and p < 0.05 was considered to be statistically
significant unless otherwise specified.
Supplementary information for this article is available online:
http://embomolmed.embopress.org.
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